Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BrUOG 401: A Phase 2 Study of Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Next Previous
X
Search
Trial Profile

BrUOG 401: A Phase 2 Study of Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Mosunetuzumab (Primary)
  • Indications Follicular lymphoma; Marginal zone B-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 12 Dec 2023 Results(As of July 2023, n-=13 patients) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 06 Jun 2023 As of Jan 2023, 7 of the planned 52 pts have been enrolled, according to trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top